🟢 OTLK is trading 7.1% up today as it rebounds from profit-taking following FDA BLA acceptance

OTLK is trading 7.1% up at $1.73, rebounding after yesterday’s profit-taking dip that followed a sharp rally driven by regulatory progress.

• The primary catalyst remains the FDA's acceptance of the resubmitted Biologics License Application (BLA) for Lytenava, which now has a set PDUFA goal date.
• Today’s upward move indicates a continuation of investor optimism as traders re-enter positions following a brief technical pullback.